Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 2017

View Archived Issues

Connexin 43 shows promise as a potential target for treating sepsis

BioCryst reports second interim analysis data from its APeX-1 phase II trial of BCX-7353

Phase I results support further study of Trovagene's PCM-075 in AML

ContraFect begins phase II study of CF-301 in S. aureus bacteremia

FDA awards orphan drug designation to EB-101 from Abeona Therapeutics

ProMIS Neurosciences selects second lead product for Alzheimer's disease

Suven Life Sciences initiates phase I trial of SUVN-911

Protagonist Therapeutics commences phase I study of hepcidin mimetic peptide

Merck & Co. and Teijin Pharma enter agreement to develop antibody targeting tau

U.S. researchers develop murine model of Crimean-Congo hemorrhagic fever

GlaxoSmithKline initiates enrollment in first-in-human study of GSK-3352589

Novel PDGFR inhibitor PK-10571 shows promise in a model of pulmonary arterial hypertension

X4 Pharmaceuticals gives update on phase I/II study of X4P-001 in RCC

Myrcludex B granted EMA PRIME eligibility

Celgene's CC-90001 preferentially targets JNK1, advances in clinical development

Arena initiates phase IIa study of APD-371 for abdominal pain in Crohn's disease

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents TLR7 agonists

Jiangsu Hansoh/Shanghai Hansoh discover novel antiviral compounds

Cip1-interacting zinc finger protein is a useful biomarker of early-stage lung cancer

Respiratory disease model for enterovirus d68 developed in mice

Study evaluating NY-ESO SPEAR T cells plus pembrolizumab begins

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...